OpenNashPodcasts

The Long Run with Luke Timmerman

Ep95: Sue Desmond-Hellmann on Becoming a Biotech Leader

26 Jul 2021 · 59m · Sue Desmond-Hellmann, Luke Timmerman · 24 quoted facts

▶ Play episodeOriginal source ↗

In brief

Sue Desmond-Hellmann argues that she became a biotech leader by combining two viewpoints: the physician who cares about one patient, and the public health thinker who cares about whole populations. Her path ran from a strict Catholic family in Reno through the AIDS epidemic in San Francisco and Uganda to drug development at Bristol-Myers Squibb and Genentech. She credits steady, practical contribution over polish.

The main arc is her move from treating patients one at a time to helping many patients through medicines. She first resisted leaving practice, kept her license as a backup, and then found industry fit her skills in statistics, safety, regulation and teamwork. At Genentech she helped build clinical capability around a strong research culture, while fast growth strained hiring and management.

Key insights

  1. Dual physician and public-health mindset shaped her career

    She says she tries to think like a public health person while empathizing like a physician, so population costs do not erase the individual patient. That framing explains why she moved from clinic to drug development and later to the Gates Foundation.

  2. Early AIDS care turned her into a Kaposi's sarcoma specialist

    She arrived at UCSF in 1982 and later ran AIDS clinic care for Kaposi's sarcoma, a cancer that appeared in patients with weakened immune systems. She calls it the clearest evidence of how much the immune system protects against cancer.

  3. Uganda marked a before and after

    She and Nick Hellman went to Uganda on a Rockefeller Foundation-funded project to study heterosexual HIV transmission. She says it moved her from trying to do well to trying to make a contribution.

  4. Industry fit her because it used her training

    At Bristol-Myers Squibb she used her MPH (master of public health) in statistics, drug safety and regulatory strategy while working on Taxol. Those same clinical trial and regulator skills were what Genentech lacked when it recruited her in 1995.

  5. Fast growth at Genentech strained hiring and management

    Art Levinson would rather leave a job open than hire a B-minus, so key roles stayed unfilled while the company grew quickly. She and others were also promoted fast and had to learn management on the job.

Questions

Who is Sue Desmond-Hellmann and why does her career matter?

She is an oncologist and public health professional who worked at Genentech from 1995 to 2009, then became Chancellor of UCSF and CEO of the Gates Foundation until January 2020. Host Luke Timmerman calls her a biotech industry legend.

Why did she leave treating patients for the drug industry?

She found at Bristol-Myers Squibb that she loved the statistics, safety and regulatory work. She says she told a patient she would try to help many cancer patients rather than one at a time.

What was Genentech like when she joined in 1995?

It was small, with about 2,000 employees by her recollection, and had three approved drugs: growth hormone, Activase and Pulmozyme. It wanted to be a cancer company but had no cancer drugs yet, and it was research-driven and 'wild west' compared with Bristol-Myers Squibb.

What did she do with AIDS patients before good treatments existed?

She used traditional chemotherapy carefully, since it could raise infection risk, and local radiation for painful lesions. She also focused on pain relief and end-of-life care because patients did not live long.

What advice does she give to young people entering biotech?

Whatever situation you are in, figure out what the effort needs and contribute as much as you can. She says to worry less about how you look and more about contributions.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Sue Desmond-Hellmann worked at Genentech from 1995 to 2009, a period the host describes as its glory days as a developer of cancer drugs.

“She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs.”

0:00:01 · Luke Timmerman · Genentech career · 1995-2009

After leaving Genentech, Sue Desmond-Hellmann became Chancellor of UCSF and then CEO of the Bill and Melinda Gates Foundation until January 2020.

“After Genentech, she served as Chancellor of UCSF and then worked as CEO of the Bill and Melinda Gates Foundation until January of 2020.”

0:00:43 · Luke Timmerman · Career path · 2020

At the time of the interview, Desmond-Hellmann sat on Pfizer's board and advised the venture firm GV, formerly Google Ventures.

“Currently, among other things, Sue is a board member for Pfizer and is an advisor to GV, the venture capital firm formerly known as Google Ventures.”

0:00:43 · Luke Timmerman · Board roles · 2021

Host Luke Timmerman credits Pfizer with helping BioNTech develop an mRNA COVID-19 vaccine in record time with very high efficacy.

“And I really want to give hats off to Pfizer for stepping up and helping BioNTech and developing this mRNA vaccine in record time and incredible efficacy.”

0:03:05 · Luke Timmerman · COVID-19 vaccine · 2020

Desmond-Hellmann's family moved from Napa to Reno when she was one, and her father and a partner opened a privately owned drugstore there.

“my parents moved to Reno. Reno was really small then and really Western and different and a new town. And my dad and his partner opened up a privately owned drugstore.”

0:09:31 · Sue Desmond-Hellmann · Early life

Desmond-Hellmann attended Catholic school for 12 years and describes her parents as extremely strict.

“I went to Catholic school for 12 years. My parents were extremely strict.”

0:10:13 · Sue Desmond-Hellmann · Education

Desmond-Hellmann was the second of seven children, and the youngest was born the summer after she finished high school.

“The youngest in my family was born the summer after I finished high school.”

0:11:55 · Sue Desmond-Hellmann · Family

Desmond-Hellmann attended the University of Nevada for college and medical school while living at home, to keep expenses low.

“A couple miles away from our house. I lived at home and was so close to running out of money by the time medical school was over.”

0:18:15 · Sue Desmond-Hellmann · Education

Working with oncologist Dr. Stephen Hall in Reno during clinical rotations led Desmond-Hellmann to switch from sports medicine to oncology.

“When I started on the clinical rotations, I worked with a physician, Dr. Stephen Hall, an oncologist in Reno.”

0:21:17 · Sue Desmond-Hellmann · Choosing oncology

In 1982 UCSF's internal medicine department accepted a trainee from the University of Nevada for the first time, Desmond-Hellmann.

“UCSF, for the first time ever in their internal medicine department, took a kid from University of Nevada.”

0:27:14 · Sue Desmond-Hellmann · UCSF residency · 1982

AIDS was first described in 1981, and Desmond-Hellmann began internship at UCSF in 1982, as the epidemic hit gay men in San Francisco.

“So HIV AIDS is described in 81. And I hit San Francisco as an intern in 82.”

0:27:55 · Sue Desmond-Hellmann · AIDS epidemic · 1982

Nick Hellman, from the University of Kentucky, trained at UCSF alongside Desmond-Hellmann and became her best friend and later partner.

“UCSF also took another kid from a state school from University of Kentucky, Nick Hellman, who became my best friend as an intern.”

0:28:41 · Sue Desmond-Hellmann · Personal life · 1982

About three years into her training, Desmond-Hellmann moved into the AIDS clinic at UCSF and treated Kaposi's sarcoma patients full time.

“by the time I was three years into my training, I actually moved into the AIDS clinic and started taking care of Kaposi's sarcoma patients full time.”

0:29:29 · Sue Desmond-Hellmann · Kaposi's sarcoma · 1980s

Kaposi's sarcoma had previously been a rare cancer in elderly Mediterranean men, but in AIDS patients with low CD4 cells it showed how the immune system fights off cancer.

“But here, as these patients had low CD4 cells and immune systems that weren't right, some came with pneumocystis cariniae pneumonia or fungal infections or other infectious diseases, but some presented with Kaposi sarcoma.”

0:30:34 · Sue Desmond-Hellmann · Immune system and cancer · 1980s

Desmond-Hellmann and Nick Hellman went to Uganda on a Rockefeller Foundation-funded project to study heterosexual HIV transmission.

“Nick and I went to study heterosexual transmission of HIV in a Rockefeller Foundation-funded project during the AIDS epidemic.”

0:33:04 · Sue Desmond-Hellmann · Uganda research · 1980s

After returning from Uganda, Desmond-Hellmann practiced as an oncologist for about two years and passed her oncology boards.

“As I like to say now, I was a real doctor for two years, a practicing oncologist. I took my boards, passed my oncology boards.”

0:37:41 · Sue Desmond-Hellmann · Clinical practice

Nick Hellman was recruited to Bristol-Myers Squibb to work on an early antiretroviral drug, which took the couple to Connecticut.

“And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs.”

0:37:41 · Sue Desmond-Hellmann · Move to industry

When Desmond-Hellmann joined in the mid-1990s, Genentech had three approved drugs: growth hormone, Activase and Pulmozyme, and no cancer drugs.

“Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme.”

0:41:42 · Sue Desmond-Hellmann · Genentech products · 1995

Desmond-Hellmann notes Genentech was founded in 1976 and that she arrived almost 20 years later.

“And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later.”

0:44:51 · Sue Desmond-Hellmann · Genentech history · 1976

Genentech's partnership with IDEC on Rituxan came around 1995 or 1996, and Rituxan was approved in 1997.

“There was not. The partnership came, I think, in 95, 96, because Rituxan was approved in 97.”

0:45:56 · Sue Desmond-Hellmann · Rituxan · 1997

Herceptin was approved in 1998, about a year after Rituxan.

“And then Herceptin came just a year later, I think, 98.”

0:46:04 · Luke Timmerman · Herceptin · 1998

Desmond-Hellmann says Genentech worked with IDEC on Rituxan's approval, and that Herceptin was harder because a diagnostic test had to be approved along with the drug.

“with IDEC, with Antonio Rio Lopez, we worked on the approval of Rituxan, which was hard, but then Herceptin, which was massively hard because we had to get the therapeutic and the diagnostic.”

0:46:33 · Sue Desmond-Hellmann · Cancer antibodies · 1990s

Genentech's R&D head Art Levinson believed in leaving a job open rather than hiring a 'B minus', which made rapid growth harder.

“Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open.”

0:48:54 · Sue Desmond-Hellmann · Hiring philosophy

Desmond-Hellmann says she vividly remembers the day Herceptin was approved and thinking of the women it would help.

“I tell people that when the day that Herceptin was approved, I still remember like it was yesterday.”

0:56:41 · Sue Desmond-Hellmann · Herceptin approval · 1998

Chapters

  1. 0:04:33Two lenses: public health and the individual patient

    Desmond-Hellmann explains why she tries to hold both views at once, which frames the rest of her career story.

    “I want to think like a public health person and empathize like a physician.”
  2. 0:09:31Growing up in a strict Reno family

    Her family's move to Reno, Catholic schooling and education-focused household shaped her drive and sense of responsibility.

    “Reno was really small then and really Western and different and a new town.”
  3. 0:24:17Choosing oncology over sports medicine

    A clinical rotation with an oncologist redirected her toward cancer care, which suited both her science interest and her bedside manner.

    “I love the patient interaction. I love the science of it.”
  4. 0:27:55Training at UCSF during the AIDS epidemic

    Starting as an intern in 1982 put her at the centre of the epidemic and led to her work on Kaposi's sarcoma.

    “heavily, heavily influenced by that terrible epidemic among gay men in San Francisco”
  5. 0:35:28Uganda as a turning point

    Work in Uganda on HIV transmission and Kaposi's sarcoma changed how she thought about what she owed the world.

    “there was sort of a before and after in our lives”
  6. 0:39:33Discovering industry at Bristol-Myers Squibb

    Working on Taxol showed her that product development fit her skills, despite her worries about leaving medicine.

    “I loved the statistics because I got to use my MPH.”
  7. 0:41:42Arriving at a small, research-driven Genentech

    She describes a company with few products and no cancer drugs that needed clinical trial and regulatory skill.

    “Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme.”
  8. 0:46:33Rituxan, Herceptin and Avastin

    The first targeted antibody cancer drugs reached the market in her time, with Herceptin needing both a drug and a diagnostic.

    “Herceptin, which was massively hard because we had to get the therapeutic and the diagnostic”
  9. 0:48:54Lessons in management and fast growth

    She describes hiring standards, learning from good and bad managers, and keeping rhythms like exercise and dinner.

    “couldn't find the right person for the job, you should just leave it open”
  10. 0:57:23Advice: contribute, don't worry about image

    Her closing advice for young people entering biotech is to focus on what the effort needs.

    “figure out what that effort needs and contribute as much as you can”

Transcript

0:00:01
Luke Timmerman

Welcome to The Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Sue Desmond-Hellmann. Sue, and I don't say this lightly, is a biotech industry legend. She's an oncologist and a public health professional by training. She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs. She was there when the company developed the original targeted antibodies for cancer, Rituxan, Perceptin, and Avastin.

0:00:43

These were drugs that transformed the treatment of cancer. They were true scientific breakthroughs and delivered the goods, improving the lives of thousands and thousands of patients around the world. After Genentech, she served as Chancellor of UCSF and then worked as CEO of the Bill and Melinda Gates Foundation until January of 2020. Currently, among other things, Sue is a board member for Pfizer and is an advisor to GV, the venture capital firm formerly known as Google Ventures.

0:01:14

In this episode, I focused mostly on Sue's early career, growing up, becoming a doctor, working on the front lines of the AIDS epidemic in San Francisco, and finding her way into industry. We talk some toward the end about her time at Genentech, which I think is of the greatest interest to listeners of this show. It would take at least two hours to cover the highlights of her career, and while I'm proud to call this show the long run, I don't think it should run quite that long.

0:01:43

Sue, as you'll hear, is a wonderful person to talk with, and I think you'll enjoy hearing about her journey and lessons she's picked up along the way. Now, for a word from the sponsor of The Long Run, DNA Script. DNA Script recently launched the Syntax System, the first ever benchtop enzymatic DNA printer, which uses its proprietary enzymatic synthesis technology. The Syntax System prints DNA on demand right in the lab. Researchers simply import their sequences, and within hours, the system synthesizes DNA oligos that can be used immediately in molecular biology and genomics workflows.

0:02:24

DNAScript's enzymatic DNA synthesis emulates nature to overcome the drawbacks of chemical-based methods traditionally used until now. Designed for fully automated walk-away synthesis, the Syntax system takes less than 15 minutes to set up with no special training to operate. With syntax, researchers can accelerate discovery with DNA on demand. For more information on DNA script, please go to www.dnascript.com. Now, please join me and Sue Desmond-Hellmann on The Long Run. Sue Desmond-Hellmann, welcome to The Long Run.

0:03:04
Sue Desmond-Hellmann

Thank you.

0:03:05
Luke Timmerman

So, Sue, before we dive in, I want to just say, you know, I know that you're on the board of Pfizer. And it's been quite an amazing year and a half or so. And I really want to give hats off to Pfizer for stepping up and helping BioNTech and developing this mRNA vaccine in record time and incredible efficacy. I can't imagine what this has been like for you as a board member to kind of witness this from a bird's eye view.

0:03:34
Sue Desmond-Hellmann

It is thrilling. It is literally the first time that I've been involved in something where I not only have so much respect for the companies involved, the people involved, not just at the the pharma companies, but also the people who have been executing the delivery and the distribution. And I got to have a vaccine. I got to have two doses of the vaccine. And like so many people, I felt emotional. I felt so grateful. I thought, you know, my life will be better and the lives of so many people will be better because of this vaccine.

0:04:14
Luke Timmerman

Yeah, yeah, for sure. And I think you kind of encapsulated it right there, like the individual and the population. Like you think about both, like your career really spans both individual medicine, the doctor to patient relationship, as well as the public health, the bigger picture implications.

0:04:33
Sue Desmond-Hellmann

No, I always feel that way. I always feel that I want to think like a public health person and empathize like a physician. And it does, if you think too much from a population standpoint, you can forget that there's a human being with a family and loved ones and things they're scared of and hopes and dreams. And if you think too much like an individual physician, you can forget that there's a bigger picture and costs and societal issues and everything else.

0:05:08

So I've always been grateful that I've gotten to see medicine and innovation from both sides.

0:05:15
Luke Timmerman

Yeah, yeah. So that's why I really want to kind of come to understand your journey a little better. And before I dive in, though, I want to say something, just how nice it is to speak to you, because like when I think of you, I think of a positive person. you and you know not in a pollyannish sort of way and not in a forced positivity that you sometimes get like you get the sense that sometimes business leaders have read a business book that said they were supposed to be positive around the troops and so that you know they they try to present a certain face but i i don't get that sense with you i get the sense that

0:05:51

you're like genuinely positive and uplifting to people around you and i wonder is that something that like you've you've always been that way? Does that come naturally? Or did you like try to consciously cultivate that?

0:06:03
Sue Desmond-Hellmann

Well, first of all, thank you. I'll take that as a compliment. I've always been that way. I've always been glass half full. What great thing is going to happen today. And so I like that about myself. And when I started caring for people who had HIV, AIDS, or cancer, I found to my surprise and delight that patients, instead of being put off by my innate optimism and sunny disposition, they liked it. One of my favorite patients told me once, can you wear that orange dress with the flowers when I come get my chemotherapy?

0:06:42

Because it makes me happy. I thought, I'll wear any dress you want. And I think, at least for me, especially when things are most difficult, What can I do? If I can show up in ways that help people enjoy their day, sign me up.

0:07:04
Luke Timmerman

You know, this reminds me one little Sue Hellman story that I was thinking about before our call was, I don't know if you remember this, but I wrote a story maybe 10 years ago about Reg Kelly at UCSF and QB3. and you were at UCSF at the time. And I uncovered some details about him, that he was born in poverty and was only really able to go to school on a scholarship that was established post-World War II for poor kids in Great Britain.

0:07:31

And I remember he wrote a note to me afterwards that said, wow, Luke, I didn't know that. Important detail about this guy who I really like and respect and I work with on an almost daily basis. So it was just like you expressing gratitude. And I just thought, you know, that's the rare kind of feedback that we get. It was, you know, it isn't like, you know, I mean, it felt genuine.

0:07:58
Sue Desmond-Hellmann

Yeah, yeah. No, it's, I think that somebody used a saying once, you saw me, you see me. And especially with people who might be in an underrepresented minority, that someone actually sees them and cares about their story like you did with Reg. That's a really valuable thing. You know, you care about me. You see me. You see who I am. And more importantly, you respect who I am and see how that adds value to the world.

0:08:32

Boy, that feels special. I'm not surprised that Reg was positive about that.

0:08:38
Luke Timmerman

Yeah. Yeah. OK, so I think we've established you're a real human being. So where does Sue Hellman come from? You are a girl from Reno. Take me back. What was the scene like where you were born and raised?

0:08:57
Sue Desmond-Hellmann

So I was actually born in Napa, California. um the the my dad was born and raised in san francisco and he went to pharmacy school in wyoming met my mom and they settled down in napa and he worked in a small pharmacy when he and another buddy noticed that the guy who ran the pharmacies sons were going to pharmacy school they thought this isn't going to be a good long-term gig so when i was one uh and had a newborn sister and a two-year-old sister.

0:09:31

My parents moved to Reno. Reno was really small then and really Western and different and a new town. And my dad and his partner opened up a privately owned drugstore. And so Reno was growing, but small. Nevada was and is a really unique state. I used to say the motto of Nevada is live and let live. When I lived there, in some counties, prostitution was legal, gambling was legal, there was no speed limit. They were sort of anti-rules.

0:10:13

But here's this kind of crazy place, and four more kids were born in Nevada. And despite this crazy place, I went to Catholic school for 12 years. My parents were extremely strict. You know, we had curfews, we couldn't go see any movies, but G movie, like, you know, the, the, the living in the, we couldn't work in a casino, I should add, living in the middle of a state that was live and let live. There was no live and let live in our house.

0:10:46

It was very strict and very, both my parents were first in their family to go to college. And in retrospect, I am so very grateful. They loved education. They loved learning. My mom was an English teacher. She loves books. And so in our house at dinnertime, you talked about school. You talked about reading books. You talked about what you learned. We talked about what my dad did at the drugstore. We ended up, as I grew up, doing odd jobs in the drugstore.

0:11:23

So it was just a great big Catholic family upbringing that I really feel privileged to have had. It was a family of seven, is that right?

0:11:37
Luke Timmerman

Seven kids, yes. And where were you in the birth order? Number two. Okay, okay. So you're not the oldest and the proverbial responsible one, But were you sort of responsible for some of your younger siblings? Did you take on those kind of tasks?

0:11:55
Sue Desmond-Hellmann

No, I was not the oldest, but I was the responsible one. The youngest in my family was born the summer after I finished high school. So a real late child. And so especially the youngest kids in the family, those of us who were older did a lot of helping mom and things like that. And, yeah, I was definitely a responsible kid.

0:12:28
Luke Timmerman

And you mentioned the, you know, the Catholic upbringing, Catholic schools. I actually was raised Catholic and attended Catholic school for a while. And, you know, I think a lot of people don't or misunderstand that or look at it from a lens from today. But what would you say were some of the values that were instilled back then? I mean, at least where I was in the upper Midwest, there was an emphasis on community service, like the Jesuit tradition, education, community service, the meek shall inherit the earth, these kind of things.

0:13:01
Sue Desmond-Hellmann

Oh, I so agree with you. And both in the grammar school and in the high school, there was very much a sense of giving back. There's a sense of, you know, what it meant to be a good person and values. I happily had a seventh grade teacher, Sister Adita Maria Rojo, who was also a physician. And so we had all sorts of different talents in the faculty as well and the teachers that we were able to interact with.

0:13:39

But our family's life also revolved around the church and the school. And so there was a lot of things that had to do with, you know, was there a fundraising drive or, you know, getting closed for something because something bad happened or things like that were really important. So it was, I think some Catholic schools have evolved to being more of what I would call a private school. And our schools were less of a feel of a private school.

0:14:16

It didn't have a huge tuition, although for us it was a lot of money. But it was more of a religious school than a private school.

0:14:26
Luke Timmerman

Yeah, yeah. And what kind of student were you?

0:14:30
Sue Desmond-Hellmann

Um, if I had one word, I'd say embarrassing. Um, uh, I was a fierce student and I'm, I'm, uh, I'm not sure where that came from, but, um, I was a big studier, big reader. I was competitive. so I did really well in school. I did really well in grammar school and then I was a valedictorian in high school and just I was very interested in school and I wanted to be good at it.

0:15:10
Luke Timmerman

Uh-huh, uh-huh. So you aim for those straight A's. But what did, what subjects really spoke

0:15:18
Sue Desmond-Hellmann

to you or inspired you? You know, it's interesting to me. I liked all the subjects. I actually liked writing and I liked reading a lot in English. But my favorite subject for sure was math. I loved math. I didn't have, and I think this was the downside of the kind of small school, I didn't have as much exposure to great chemistry, biology, things like that. But math, I had some really good math teachers, a great geometry teacher, and I loved math.

0:16:06

And my dad was really good at math. And, you know, in families, my mom would say, oh, you're just like your dad. And so I took it as, you know, I'm like my dad. He's good at math. I'm good at math. It wasn't until I went to college and particularly took organic chemistry and some other courses in science that I had more of an affinity for science. But before that, my favorite was math.

0:16:40
Luke Timmerman

Okay. So you're valedictorian. You're obviously going places. You're ambitious as a student. How did you – when did you decide you wanted to become a doctor? And was that at University of Nevada, Reno?

0:16:56
Sue Desmond-Hellmann

Oh, no. We have a funny picture of me with a plastic stethoscope. And I think I was eight or nine, something like that. And I remember having a conversation with my dad about whether it was a better job to be a doctor or a pharmacist. My memory of this, which is probably would be different. But my memory was him reminding me that the doctors gave the orders, and that was kind of a good thing. But I wanted, for sure, I was going to college because I was on my way to medical school.

0:17:41

That was not in question for me.

0:17:45
Luke Timmerman

So you're pre-med from early days as an undergrad?

0:17:49
Sue Desmond-Hellmann

Completely. In fact, in college, and again, in retrospect, it might have been good to be a little more broad and a little more educated in arts and sciences. But I went to college for three years because I wanted to get to medical school.

0:18:08
Luke Timmerman

Okay. Okay. So how did you end up at University of Nevada, Reno? Just the hometown school?

0:18:15
Sue Desmond-Hellmann

A couple miles away from our house. I lived at home and was so close to running out of money by the time medical school was over. I had a couple of student loans, but not giant student loans. But I was I was going to school where where I could decrease the expenses.

0:18:37
Luke Timmerman

Yeah. Yeah. Well, and with the family, a large family, you can't just pay private school tuition for all seven kids.

0:18:44
Sue Desmond-Hellmann

No, I was very, I was really concerned about my parents and especially having so many kids. And all, I think every single one of us went beyond college. So it was important to me that especially if my dad was going to retire someday and they could stop worrying so much about their kids and paying for things, that I not contribute to that being harder.

0:19:22
Luke Timmerman

Uh-huh. Uh-huh. Don't want to be a burden. I get it. Um, so you kind of hurry your way three years through your undergraduate degree, uh, and go to medical school. And where was that?

0:19:35
Sue Desmond-Hellmann

University of Nevada.

0:19:37
Luke Timmerman

Okay. So you still stayed at home?

0:19:39
Sue Desmond-Hellmann

I, I lived at home the entire time at medical school. Yeah, I did not. In fact, it's it's funny in my when I went to UCSF, you know, I'm going to be an intern and in internal medicine. It was the first time I had lived outside of my parents' house was then after after medical school. And in fact, when I went to University of Nevada for undergrad, it was the first time I didn't wear a uniform to school.

0:20:16
Luke Timmerman

So there was a lot of culture change happening for you when you made that move to residency. Yeah. You would have been, what, mid to late 20s then?

0:20:25
Sue Desmond-Hellmann

I was. No, I was. Because remember, I skipped a year. So when I started, I think I was 25, something like that. But, yeah, no, my husband laughs at he claims. And I have seen, you know, we didn't take pictures as much because we didn't have smartphones. But I've seen a picture or two. And I think my husband's claim, sadly, is right, which is I still looked like a Catholic school kid. Just very, you know, very naive and very sheltered.

0:21:01

And, you know, I was focused on school and still helped my mom out a little bit at home and spent a lot of time in the library.

0:21:12
Luke Timmerman

So how did you end up going to UCSF and what kind of doctor did you want to become there?

0:21:17
Sue Desmond-Hellmann

Well, I evolved during medical school. When I went to medical school, I wanted to be a sports medicine doctor or an orthopedist because I'm really into sports and thought that would be a great thing. When I started on the clinical rotations, I worked with a physician, Dr. Stephen Hall, an oncologist in Reno. And, oh, my gosh, that was life changing. I mean, working with him and seeing his bedside manner, his intelligence, his knowledge of medicine, I changed to thinking that oncology would be great.

0:21:59

And so I knew I wanted to do internal medicine. And then if I specialized, I would do oncology. But you asked about UCSF.

0:22:07
Luke Timmerman

Well, no, let's back up here a little bit, Sue, because you were thinking of sports medicine. I mean, when I think of that, I think of, you know, bandaging up a sprained ankle, sprained knee. I mean, taking care of athletes, it's an important medicine. But something intrigued you here about oncology.

0:22:24
Sue Desmond-Hellmann

Oh, yeah. So for me, I had this dreamy thing about sports medicine that it was really interesting and I liked sports. And here's where I was off. First of all, I like sports. That's different than liking sports medicine. I still like sports. I still follow sports. I still run and cycle and do things like that. So I think that I was just young and I was just confused about what a day would be like. The other thing that I underestimated is, you know, I'm not, you know, a real, I don't have great hand-eye coordination and I'm not very strong.

0:23:05

So I still remember, especially as a medical student, being in the operating room and somebody getting out like a mallet to do something for a hip operation. I'm thinking this specialty involves tools. I don't know anything about tools.

0:23:20
Luke Timmerman

And wait until like you have a wrestler with a separated shoulder you got to put back in.

0:23:24
Sue Desmond-Hellmann

I know. And I thought I would constantly be asking for help because I'm completely not strong enough, not dexterous enough. Plus, I found surgery. you know you gown and glove and get in a room um for hours on end holding a retractor shoot me through the head i just i actually didn't love surgery even though it's very dramatic and especially students always put it on a pedestal now oncology on the other hand there was dna there was uh cell replication there was there was all this great research going on there was And the patients, when they face their own mortality and the fright of being told that you have cancer, could use a doctor with a good bedside manner, which,

0:24:17

you know, unlike the thing with the hammer and everything, I can do that. So I love the patient interaction. I love the science of it. I love that it was a specialty that I thought was going to have positive change and improvements. So everything about me and oncology was a better fit than sports medicine.

0:24:41
Luke Timmerman

And this would have been something like the early 80s when we're beginning to learn just the beginnings of oncogenes and tumor suppressor genes. And these things are getting published. And at the time, all you had for tools was classic chemotherapy and radiation, right?

0:25:01
Sue Desmond-Hellmann

Exactly. With a lot of side effects and the modern chemotherapy, you know, things like gemcitabine or Taxol or medicines like that were not around. So you had a lot of aging chemotherapy drugs that were being used in different combinations to, you know, do the best you could for patients. but radiation surgery, other things. So there was also a lot of end-of-life care because there wasn't the kind of toolkit that we have today.

0:25:34
Luke Timmerman

DNA Script recently launched the Syntax System, the first-ever benchtop enzymatic DNA printer, which uses its proprietary enzymatic synthesis technology. The Syntax System prints DNA on demand right in the lab. Researchers simply import their sequences, and within hours, the system synthesizes DNA oligos that can be used immediately in molecular biology and genomics workflows. DNAscript's enzymatic DNA synthesis emulates nature to overcome the drawbacks of chemical-based methods traditionally used until now. Designed for fully automated walk-away synthesis, the Syntax system takes less than 15 minutes to set up with no special training to operate.

0:26:18

With Syntax, researchers can accelerate discovery with DNA on demand. For more information on DNA Script, please visit www.dnascript.com. And if you like listening to The Long Run, you'll love reading Timmerman Report. This is the place where you'll get to read my weekly columns, regular profiles of interesting biotech startups, and insightful commentary from a diverse cast of contributing writers who I cultivate and edit. TR is a reader-supported publication. You can support quality, independent biotech journalism like this through purchasing an annual subscription for $169 a year.

0:26:59

Go to TimmermanReport.com for more. Group discounts are available. So you move on to UCSF. And what happened next for you?

0:27:14
Sue Desmond-Hellmann

Well, so many things happened in 1982 when I came to UCSF. The first thing that I was so proud of and so wanted to do my best and represent Nevada well is, to my great surprise and delight, UCSF, for the first time ever in their internal medicine department, took a kid from University of Nevada. It was so exciting, and I was so very happy to be at UCSF because it's a great institution. It just was, for me, like going to the big leagues.

0:27:55

Happily, because I was, for the first time ever, out of the house, my aunt and uncle and my grandma lived down the street from UCSF. So that was convenient. And I was grateful to have family in the city. But two other seismic events happened in 1982. One is, and we just passed the 40th anniversary of HIV AIDS being described. So HIV AIDS is described in 81. And I hit San Francisco as an intern in 82. And so the entire training program was heavily, heavily influenced by that terrible epidemic among gay men in San Francisco.

0:28:41

And the other thing was that that UCSF also took another kid from a state school from University of Kentucky, Nick Hellman, who became my best friend as an intern. And we've been together ever since. So that was good news as well.

0:29:00
Luke Timmerman

Well, that is a great story and that you do have those common backgrounds. But I find this really interesting that this is where things get interdisciplinary for you. Because at this time, you're still training to be an oncologist, right? But HIV AIDS is breaking out and manifesting with Kaposi's sarcoma in many cases, right?

0:29:29
Sue Desmond-Hellmann

That's right, Luke. So by the time I was three years into my training, I actually moved into the AIDS clinic and started taking care of Kaposi's sarcoma patients full time. And so that was my experience at UCSF is that there were so many patients with this AIDS-related cancer and some patients with lymphoma, although many fewer, that that was my specialty. And the first grant that I ever got was a grant to study capsic sarcoma.

0:30:12
Luke Timmerman

so in a way you're kind of like one of the early immuno oncologists i mean if you could just speak for a second on the science here like there was something going on with immune dysregulation which caused this particular type of of cancer to to emerge it was so interesting if you remember

0:30:34
Sue Desmond-Hellmann

the there was a form of capsaeus sarcoma that we later called mediterranean or typical capsaeus sarcoma that had been a very rare event in elderly males in the Mediterranean area. But here, as these patients had low CD4 cells and immune systems that weren't right, some came with pneumocystis cariniae pneumonia or fungal infections or other infectious diseases, but some presented with Kaposi sarcoma. And so it was definitely the most obvious evidence of the importance of your immune system in fighting off a cancer that if we didn't have an intact immune system in this way, many more people would experience.

0:31:24
Luke Timmerman

So, I mean, you didn't, again, have a lot of great tools in these years. What did you do for

0:31:30
Sue Desmond-Hellmann

these patients? So we used some chemotherapies that we had, traditional chemotherapies, but we always were balancing that with the fact that that would make people sick and potentially put them at risk for the infectious diseases that you see with HIV AIDS. So we also used some local radiation, especially if there was something that was painful. But we didn't have a lot of tools. And back in the early days of HIV, it's hard to even think about this now that we have highly active antiretrovirals.

0:32:12

And I will say that the patients just didn't live very long, treatment or no treatment. So as I cared for those patients before we had good tools, I would focus on pain relief, end-of-life care, symptom improvements, and make sure they had pain meds and things like that because these were bad days.

0:32:36
Luke Timmerman

But at UCSF, you're surrounded by a lot of great biologists as well as physicians. And this is when you're kind of becoming a physician scientist. in this very highly uncertain arena of HIV and all its downstream manifestations. You made a move to go to Uganda. And I think, did you go there with Nick as well?

0:33:04
Sue Desmond-Hellmann

Yes. Nick and I went to study heterosexual transmission of HIV in a Rockefeller Foundation-funded project during the AIDS epidemic.

0:33:15
Luke Timmerman

Now, what drew you to Uganda? What were you expecting to do and learn? And how did it turn out for you?

0:33:25
Sue Desmond-Hellmann

Well, what drew both of us in the original intent was to ask the question, is there heterosexual transmission of HIV going on in Africa? In the U.S., we had these risk groups that we were pretty clear about. But what was happening in Africa and was very frightening was evidence of heterosexual transmission. And so the original intention, and that remained, was to try and understand things like sexually transmitted diseases and other behaviors that might be contributing to a much higher rate of sexual transmission through heterosexual interaction.

0:34:05

And then secondarily, I had moved my grant to study Kaposi's sarcoma to Uganda. So we were seeing a massive number of patients with Kaposi's sarcoma. And in addition to the Mediterranean form of Kaposi's sarcoma, there's also an African form of Kaposi's sarcoma. And in that milieu, it was literally Kaposi's sarcoma was just exploding in Uganda. and so trying to understand that, trying to help care for those patients and do that research

0:34:40
Luke Timmerman

was really an important part of the project. You know, Sue, I actually visited Uganda a couple years ago before my Kilimanjaro trip and I visited the Uganda Cancer Center where I know you trained or you did your work because the tour guide told me, he said, you're sitting in the same seat that Sue was in, you know, you had, I guess, been on a, you had visited there again, many years later to check in. But I mean, how did this experience shape you?

0:35:13

And because I mean, again, you said you were kind of a naive, sheltered person from Reno, Nevada. Now, all of a sudden, the world's opening up, you go to San Francisco, you're spending time in Africa, treating this, this huge

0:35:28
Sue Desmond-Hellmann

epidemic. I will say, and this is not an exaggeration, for Nick and I, having gone to Uganda seven years after we got to UCSF, there was sort of a before and after in our lives. Before we went, we were doing, you know, try and get A plus in school, get a good grade on the test, do your training. And then we hit San Francisco in this terrible epidemic. So for us going to Uganda was a chance to contribute.

0:36:05

It was a reminder of how good we have it here and how easy our lives are. And it just was a very powerful, a powerful way to think about how what the world should expect from you if you're given a lot I think that you talked about turning into a physician scientist I think that for me I wouldn't characterize my evolution so much as turning into a physician scientist I think that happened more at Genentech, honestly.

0:36:46

I think my training and going to Uganda in the next few years moved from doing a good job to making a contribution.

0:36:59
Luke Timmerman

I see. Yeah. You see that there's a really big wider world out there of patients in need.

0:37:07
Sue Desmond-Hellmann

Yeah. Most people don't get all the good stuff. People now use words like privilege. I think that it was sort of like smack in the face. Okay, privilege like crazy. Now what are you going to do? So who cares if you're smart? Who cares if you know how to do X, Y, or Z? Who's going to benefit? What's going to be better in the world as a result of you?

0:37:35
Luke Timmerman

Yeah, yeah. So you do a couple years there in Uganda. And what was your next move then?

0:37:41
Sue Desmond-Hellmann

It was going back to UCSF and finding out that they didn't have a global health program and didn't know what to do with us. So we went into practice for a couple of years. As I like to say now, I was a real doctor for two years, a practicing oncologist. I took my boards, passed my oncology boards. And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs. And I was the trailing spouse and got put on

0:38:12
Luke Timmerman

working on Taxol. Oh, okay. So the newer chemotherapy of the time.

0:38:21
Sue Desmond-Hellmann

The newer chemotherapy, yeah. And I had actually heard about it when I was in practice and was really intrigued by it and got to work on Taxol when it was only approved initially for ovarian cancer. And I worked on the approval with my colleagues for breast cancer in the US and Europe.

0:38:42
Luke Timmerman

So you're making the move here from being a practicing physician, you and Nick, to going over to industry. I mean, that was a pretty big move. How did you think about

0:38:52
Sue Desmond-Hellmann

the pros and cons of that? We had a lot of uncertainty. I had a lot of uncertainty about whether or not it was going to be the right thing to do. So I kept my medical license and I participated in the heme clinic at the West Haven VA because we were in Connecticut. So I had a backup strategy because I really wasn't sure that things would work out because I didn't know that much about industry. And so there was a lot of uncertainty and a lot of concern about what, you know, we put on a black hat and become the bad guys, that kind of thing.

0:39:27
Luke Timmerman

So how long were you there? And what did you pick up and really learn about industry in that first

0:39:33
Sue Desmond-Hellmann

stint at BMS? We were there for two years and I loved it. I loved everything about being at BMS. I loved the statistics because I got to use my MPH. I loved drug safety because it was all about medicine. I loved the regulatory side of things because it was strategic. I loved my colleagues because they were so knowledgeable and they knew a lot more about things than I did and they were generous enough to teach me.

0:40:03

I did not like the snowstorms in Connecticut. The weather was bad and we were far away from home. And it was only because Genentech recruited me that we left. Because I just, I thought Bristol Myers Squibb, Taxol, the team, the people, and working on product development. I thought, what took me so long to figure out that this is the perfect job for me?

0:40:28
Luke Timmerman

but you um this is a point where you're no longer um having that individual doctor patient relationship or or are you still treating patients kind of part-time while you're focused on these these bigger picture issues how to develop a new medicine that will help

0:40:46
Sue Desmond-Hellmann

many many people yeah you know i did a little bit of clinical work when i was in connecticut not a lot. And I discovered that unlike some physicians who successfully do product development and clinical work, many cancer patients are just too sick to have their doctors, you know, super part-time. So I kind of gave up on that idea and got comfortable with what I told one of my patients when I left practice, which was that I would try and do something for her and lots of other cancer patients rather than one patient at a time.

0:41:23
Luke Timmerman

Okay. And then you go to Genentech. And I think this was mid-90s, 95, is that right? Okay. So describe the scene. What did you discover when you arrived back there in South San Francisco? And what were you supposed to do?

0:41:42
Sue Desmond-Hellmann

Well, it was so very different than Bristol-Myers Squibb. It's just impossible to tell you how different it was. First of all, it was tiny. You know, when I left Genentech, it was 11 ,000. I think when I came, it was about 2 ,000. So it was way smaller. Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme. they wanted they had aspirations to be a cancer company they had no cancer drugs and they had gamma interferon in the pipeline and it was it was very much a a very research driven research oriented company.

0:42:34

Art Levinson was the head of R &D. And it was pretty wild west compared to the buttoned up Meyers Squibb. So it was really different. Yeah. So what was an oncologist with this HIV

0:42:52
Luke Timmerman

background and a master's in public health and statistics? How were you supposed to fit in?

0:43:00
Sue Desmond-Hellmann

you know it's funny that that um i will say that if if i had one attribute that i'm glad i had i just rolled up my sleeves and said look i just got through with all this stuff at bristol meyer squib i know how to do x y and z you know you're doing this can i help you know can i write a protocol can i help you with this can i think through with you on that.

0:43:28

And so I just dove in the pool and started swimming, you know, it's, and, and the happy thing was, and I think this is the reason why I did well at Genentech, what they needed, I had learned how to do at BMS, you know, so they needed a lot more work on the skillset of doing clinical trials, interacting with the regulators, Because the background and the chief medical officer at the time was a pediatric endocrinologist. They had sort of grown up from the growth hormone days where you did these relatively small trials and a specialized group of kids.

0:44:08

And then they did the TIMI and GUSTO trials with cardiologists and cooperative groups. And then pulmazine was also super specialized. So branching out to things that were like a company-sponsored trial or things like that, we're just really new to Genentech, really new to Genentech.

0:44:29
Luke Timmerman

Well, and there were the old stories about, you know, the recombinant insulin where they partnered up with Lilly, you know, years ago. And it was, you know, the original like science culture. I mean, they definitely had the science culture, but not really its own clinical development organization for oncology. not in the well-oiled machine that it would later become.

0:44:51
Sue Desmond-Hellmann

Exactly. And you know what's great is that's what we built. And what I realized over time, especially as I spent more time with the research group, is you can build a clinical group and you can build that capability, not fast, but relatively fast. And you can get some muscle doing that over and over again. And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later. That research muscle, you know, you can't grow that overnight.

0:45:26

And boy, were they and are they good at research? I was just and I was so excited to spend time with scientists and to work on what I think you would call translational research. That was fun. That was inspiring.

0:45:44
Luke Timmerman

At that time, mid-90s, you get there. Was there already a partnership in place with IDEC on Rituxan, the original monoclonal antibody for cancer?

0:45:56
Sue Desmond-Hellmann

There was not. The partnership came, I think, in 95, 96, because Rituxan was approved in 97.

0:46:04
Luke Timmerman

And then Herceptin came just a year later, I think, 98.

0:46:07
Sue Desmond-Hellmann

98, that's right. Your memory's good.

0:46:10
Luke Timmerman

So you had, I mean, two in retrospect, monumental advancements, monoclonal antibodies for cancer, which people by this point had been talking about for about 20 years, hadn't really, you know, manifested in the form of approved therapies. And these needed to be taken across the finish line and brought all the way to the market for patients.

0:46:33
Sue Desmond-Hellmann

That's right. So with IDEC, with Antonio Rio Lopez, we worked on the approval of Rituxan, which was hard, but then Herceptin, which was massively hard because we had to get the therapeutic and the diagnostic. And then not that long afterwards, Avastin.

0:46:54
Luke Timmerman

Yeah, yeah, the VEGF.

0:46:56
Sue Desmond-Hellmann

The VEGF antibody.

0:46:58
Luke Timmerman

That was a few years later. um but now so by the time i came around and started writing about genentech it was later days and those were kind of the big three products at the company and the company was known for um it's it's uh you know exceptional work in cancer um but what were some of the key things you learned in those uh as you kind of you know rose through the ranks and and probably i'm sure you had to make some hard decisions about things that, you know, drugs that you were going to put on the shelf.

0:47:32

I mean, it wasn't all, you know, rainbows and roses. Definitely not. So the, I, you know,

0:47:40
Sue Desmond-Hellmann

there's so many things I learned that the, the, the most important thing goes back to that translation and the science and, and just doing your best to let the science and the data drive your decision making and the calls you make and what you thought you could do. I think that was really important. The other thing was just that, and this is one of the things I actually ended up liking a lot about pharma and biotech is there's, you can take a lot of talented people, they each play a role and make something wonderful happen.

0:48:17

And we just ended up building a great team with people in so many roles on that team who knew what they were doing, which mattered a lot and made a huge difference. That was a big, big deal. The things that I think that we were probably naive from a commercial standpoint on how we thought about commercialization. I think we got better over time. That improved at the company because we just didn't have a giant tradition of this big oncology portfolio.

0:48:54

And then as we grew, we had two problems as we grew. One is there were jobs where we couldn't find the right person for the job. And Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open. You shouldn't take, you know, B minus. And so we really struggled because we were growing so fast to find the right people. And then just management wise, lots of people, me included, got promoted really fast and got these big jobs and trying to make sure that you could do all aspects of the job, be a great manager, give people room to grow.

0:49:34

You know, those are things I think any company that's growing fast struggles with.

0:49:38
Luke Timmerman

That sounds like putting a lot of stress on your A players.

0:49:43
Sue Desmond-Hellmann

You know, the thing that, as I look back at the time I was there, it was a wonderful time. And I worked harder than humans should work.

0:50:00
Luke Timmerman

Yeah, yeah. But you eventually learned to become a manager. and part of that job is delegating. How did you learn about what it takes to be a good manager?

0:50:13
Sue Desmond-Hellmann

I would say a combination of good role modeling and bad role modeling were really important. Art was my boss for most of the time I was at Genentech and there were things he did that I thought were really positives. I'll give you an example. He would often say, you don't think you're capable of that, but I think you're capable of that. I'll help you. Give it a try. You know, so he had this really nice way of encouraging, taking some risks.

0:50:44

I also had people either that I managed or other colleagues who I would see the results of bad management, like people who felt threatened by great people instead of being proud of having great people, things like that. And then I really liked working with HR. I learned a lot from experienced expert colleagues in HR and read a bit about trying to be a better manager. So I wanted to be good at management. It seems like it made a big difference.

0:51:14

And I worked hard to try and be good at it. And when you're having a bad day

0:51:21
Luke Timmerman

or something goes sideways, how do you handle it personally? And, you know, how do you you know, model that, I guess, for your team? That's probably for me evolved over the years,

0:51:38
Sue Desmond-Hellmann

but I think the, I'd say today versus 10, 15 years ago, staff really expect a lot more transparency. So, would expect you to share that with them in a respectable, you know, thoughtful way. I've always tried to enjoy colleagues and enjoy other people. And that's meant a lot to me if I'm having a bad day. I've used exercise since forever, since back when I thought I'd be a sports medicine doctor for stress relief. I think it's, you can't have a bad day if you get a good run in or a good bike ride in.

0:52:19

So things like that. And then I, my husband and I have had a rule that we've tried really hard, especially over time, to have dinner together. And, you know, not have the TV on, not have anything going on, nobody working. And that just feels like towards the end of the day, you have a treat. It's always nice to have a treat. A little downtime. A little downtime, a little family time. That's important.

0:52:47
Luke Timmerman

Even when you were busier than you could ever imagine?

0:52:51
Sue Desmond-Hellmann

You know, the one thing I learned in medical school is, and this was for me, you know, people would pull all-nighters. I had a rule that I went to bed at 11 o 'clock. If I had a good night's sleep, I could do anything. And I feel the same way about having a nice dinner or a run or things like that. I could convince myself I should be working or I could clear my brain and realize that when I work again, I'll be twice as good.

0:53:19
Luke Timmerman

Well, and it's sort of, you can file this one under Rome wasn't built in a day, right? I mean, if you're trying to make a difference for a lot of people, it's not going to happen in your all-nighter.

0:53:30
Sue Desmond-Hellmann

You know, we have a saying in medicine, check your own pulse first. It's a good saying.

0:53:39
Luke Timmerman

We're almost out of time, Sue. But, you know, you moved on after Genentech, Roche acquired the company, and you went to UCSF and Gates Foundation. And now you're serving on some boards. I mean, and the amazing, coming back to what we talked about at the beginning, I mean, just how amazing this past year and a half has been in terms of the industry's ability to take a brand new virus and turn it around with, like, new treatments, new diagnostics.

0:54:08

remarkably effective vaccines. Do you ever look around in just awe or amazement at what the industry has become in your time?

0:54:17
Sue Desmond-Hellmann

You know, that is so well said. The fact that we have a group of companies, and it is, I mean, I'm a globalist, not a nationalist, but it's a huge American asset. And it's a huge global asset to have companies worldwide that have the capability to do what these companies have done for COVID. I think it is. But, you know, add that to what happened with antiretroviral therapy for HIV. Add that to what happened with immuno-oncology.

0:54:54

There's so much more that can be done for people who are sick or who we want to prevent from getting sick. It's just a thing of beauty. I I'm in awe of what's possible today. And, you know, I was at a meeting this morning where I was listening to some of the gene editing things going on and thinking, oh, my goodness, who'd have thought? You know, I think it's just outstanding.

0:55:24
Luke Timmerman

Yeah, you know, I'm a bit reflective, too, having written about the industry now for 20 years. I mean, I haven't been around as long. But the things that used to make news 20 years ago are nothing but a brief or a footnote today. The things that are happening today are just absolutely mind-boggling order of magnitude better. and when you start to look at the companies that are out there today and have a chance to make a difference for a lot of different illnesses that we never had anything for, kind of like when you started.

0:55:57

I mean, the next 20 years, it'll be something to see.

0:56:02
Sue Desmond-Hellmann

No, it will be, and I'm excited for humanity, but I'm also excited for students and young people who will get to experience this and drive this. And that's the thing that I haven't said that I really think hopefully is maybe obvious, which is it is so much fun when you get to use science and work with colleagues to make something special happen. And it is just the sense of purpose, the sense of accomplishment and meaning that that has.

0:56:41

I tell people that when the day that Herceptin was approved, I still remember like it was yesterday. I thought that of all the women who would be able to get her septum in the future, and that that would change their lives. And it just, to me, it was like, and I got to be part of this. I was just so excited.

0:57:07
Luke Timmerman

And it did. And a lot more came. Yeah. I'm sure you must get requests for advice from young people, and there are quite a few that listen to this show. Do you have any standard bits of advice for young people about to embark on careers in biotech?

0:57:23
Sue Desmond-Hellmann

The thing is, and I think this is really important, they no matter what situation you find yourself in, like, you know, going to Bristol-Myers Squibb, I had no idea what it was going to be like. Moving back and going to Genentech, I had no idea. No matter what the situation is, figure out what that effort needs and contribute as much as you can. Like just figure out how you're going to contribute. And if you need to contribute differently or better, learn how to do that.

0:57:55

And the worry less about like how you look or, you know, perceptions or things like that, worry more about contributions.

0:58:09
Luke Timmerman

It sounds a lot like the growth mindset that Carol Dweck at Stanford has popularized. Don't be afraid of these things that you might feel a little uncomfortable with. You might not be the best math person or something else and just give it a go.

0:58:30
Sue Desmond-Hellmann

Yeah, contribute. Maybe it rubbed off from Satya and my colleagues at Microsoft when I was in Seattle. They loved that.

0:58:39
Luke Timmerman

Sue Desmond-Hellmann, thank you so much for spending time today on The Long Run.

0:58:43
Sue Desmond-Hellmann

Thank you for having me. I really enjoyed it, Luke. Thanks a lot.

0:58:49
Luke Timmerman

Thanks for listening to The Long Run, a production of Timmerman Report. Pedro Rosado of Headstepper Media was the sound editor. Music is from D.A. Wallach. See you next episode. you